Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Active, not recruiting · NCT05397639 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type | Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, nervous system disorder | Active, not recruiting | Phase 3 | 2026-09-15 | NCT05397639 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Suven Life Sciences Limited | 2 |
44 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.